Karen Snyder - Concepedia

Author

Karen Snyder

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

K SNYDER, K Snyder, Karen M. Snyder, Karen Snyder

Publications

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)United States Military Academy University of Oxford HealthInsight Ghent University Hospital

About

Karen Snyder is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacotherapy, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	665
2	Natural Sciences	1	1	99
3	Biochemistry	1	1	99
4	Diabetes	1	1	184
5	Neurology	1	1	71

Karen Snyder

Publications

Citations

H-Index

Page 1

	Year	Citations
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses Gary Herman, C. Melinda Stevens, Koen Vandyck, Clinical Pharmacology & Therapeutics	2005	514
Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes Gary Herman, Arthur Bergman, Catherine Stevens, The Journal of Clinical Endocrinology & Metabolism	2006	498
Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers Arthur Bergman, Catherine Stevens, Yanyan Zhou, Clinical Therapeutics Pharmacological StudyMedicineHealthy Male VolunteersPlacebo-controlled StudyPharmacotherapy	2006	265
Pharmacokinetics and Pharmacodynamic Effects of the Oral DPP‐4 Inhibitor Sitagliptin in Middle‐Aged Obese Subjects Gary Herman, Arthur Bergman, Fang Liu, The Journal of Clinical Pharmacology Middle‐aged Obese SubjectsPharmacotherapyInsulin SignalingObesityMetabolic Syndrome	2006	184
Efficacy and Safety of Intranasal Peptide YY3–36 for Weight Reduction in Obese Adults Ira Gantz, Ngozi Erondu, Madhuja Mallick, The Journal of Clinical Endocrinology & Metabolism	2007	160
Multiple-Dose Pharmacodynamics and Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Subjects Rajesh Krishna, AJ Bergman, Bo Jin, Clinical Pharmacology & Therapeutics High-density LipoproteinHealthy SubjectsBiochemistryPharmacological StudyMedicine	2008	99
Cerebrospinal Fluid Biomarkers Distinguish Postmortem-Confirmed Alzheimer's Disease from Other Dementias and Healthy Controls in the OPTIMA Cohort Jeffrey L. Seeburger, Daniel Holder, Marc Combrinck, Journal of Alzheimer s Disease	2015	97
High Resolution Discovery Proteomics Reveals Candidate Disease Progression Markers of Alzheimer’s Disease in Human Cerebrospinal Fluid Ronald C. Hendrickson, Anita Y. H. Lee, Qinghua Song, PLoS ONE Human Cerebrospinal FluidNeurochemical BiomarkersProteomic TechnologyAlzheimer's DiseaseHuman Csf	2015	71
Single‐dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects Rajesh Krishna, Amit Garg, Deborah Panebianco, British Journal of Clinical Pharmacology	2009	50
Comparative Inhibitory Activity of Etoricoxib, Celecoxib, and Diclofenac on COX‐2 Versus COX‐1 in Healthy Subjects Jules I. Schwartz, Aimée Dallob, Patrick Larson, The Journal of Clinical Pharmacology Cox‐2 Versus Cox‐1Healthy SubjectsChemoprevention StrategyWhole BloodPharmacotherapy	2008	46

Page 1